title: Antinociceptive effects of neuropeptide Y and related peptides in mice.
abstract: This study compares the antinociceptive and orexigenic activities of NPY and analogs after intracerebroventricular administration in mice. NPY had an antinociceptive action in the mouse writhing test which was not affected by prior treatment with naltrexone, yohimbine, idazoxan or reserpine. A detailed examination revealed that NPY (0.023-0.7 nmol), PYY (0.007-0.07 nmol), NPY2-36 (0.023-0.23 nmol) and the Y1 agonist [Leu31, Pro34]-NPY (0.07-0.7 nmol) all produced a dose-dependent and complete suppression of acetic acid-induced writhing. In contrast, the Y2 agonist, NPY13-36, had little or no antinociceptive effect. As shown by their ED50 values, the relative potency of the peptides was PYY > NPY2-36 > or = NPY > [Leu31, Pro34]-NPY > > NPY13-36, suggesting that a Y1 rather than a Y2 or Y3 receptor subtype was implicated in the antinociceptive action. Thereafter, all peptides were assessed for their effects on food intake. With respect to dose and peptide specificity, the hyperphagic effects of NPY and related peptides paralleled those on nociception, suggesting a common receptor mechanism. However, a purported NPY antagonist, [D-Trp32]-NPY, attenuated NPY's effect on feeding yet this same peptide elicited a dose-dependent inhibition of acetic acid-induced writhing, suggesting some molecular distinction between antinociception and stimulation of food intake.
authors.affiliation: Department of Pharmacology, Institut de Recherche Jouveinal, Fresnes, France.
authors.forename: P
authors.initials: P
authors.lastname: Broqua
authors.forename: J G
authors.initials: JG
authors.lastname: Wettstein
authors.forename: M N
authors.initials: MN
authors.lastname: Rocher
authors.forename: B
authors.initials: B
authors.lastname: Gauthier-Martin
authors.forename: P J
authors.initials: PJ
authors.lastname: Riviere
authors.forename: J L
authors.initials: JL
authors.lastname: Junien
authors.forename: S G
authors.initials: SG
authors.lastname: Dahl
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D004435:Eating / Q000187:drug effects; D005768:Gastrointestinal Hormones / Q000494:pharmacology; D019329:Idazoxan / Q000494:pharmacology; D007276:Injections, Intraventricular; D008297:Male; D051379:Mice; D009478:Neuropeptide Y / Q000031:analogs & derivatives* / Q000494:pharmacology*; D009619:Nociceptors / Q000187:drug effects*; D010446:Peptide Fragments / Q000494:pharmacology*; D019894:Peptide YY; D010455:Peptides / Q000494:pharmacology; D018341:Receptors, Adrenergic, alpha-2 / Q000378:metabolism; D017476:Receptors, Neuropeptide Y / Q000378:metabolism; D011957:Receptors, Opioid / Q000378:metabolism; D015016:Yohimbine / Q000494:pharmacology
chemical_list: D000317:Adrenergic alpha-Antagonists; D005768:Gastrointestinal Hormones; D009478:Neuropeptide Y; D010446:Peptide Fragments; D010455:Peptides; D018341:Receptors, Adrenergic, alpha-2; D017476:Receptors, Neuropeptide Y; D011957:Receptors, Opioid; C062924:neuropeptide Y (13-36); D019894:Peptide YY; C062259:neuropeptide Y, Leu(31)-Pro(34)-; D015016:Yohimbine; D019329:Idazoxan